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It is well known that certain active ingredients of the plants of Cannabis genus, i.e., the 
“phytocannabinoids” [pCBs; e.g., (−)-trans-Δ9-tetrahydrocannabinol (THC), (−)-canna-
bidiol, etc.] can influence a wide array of biological processes, and the human body is 
able to produce endogenous analogs of these substances [“endocannabinoids” (eCB), 
e.g., arachidonoylethanolamine (anandamide, AEA), 2-arachidonoylglycerol (2-AG), 
etc.]. These ligands, together with multiple receptors (e.g., CB1 and CB2 cannabinoid 
receptors, etc.), and a complex enzyme and transporter apparatus involved in the syn-
thesis and degradation of the ligands constitute the endocannabinoid system (ECS), 
a recently emerging regulator of several physiological processes. The ECS is widely 
expressed in the human body, including several members of the innate and adaptive 
immune system, where eCBs, as well as several pCBs were shown to deeply influence 
immune functions thereby regulating inflammation, autoimmunity, antitumor, as well 
as antipathogen immune responses, etc. Based on this knowledge, many in vitro and 
in  vivo studies aimed at exploiting the putative therapeutic potential of cannabinoid 
signaling in inflammation-accompanied diseases (e.g., multiple sclerosis) or in organ 
transplantation, and to dissect the complex immunological effects of medical and 
“recreational” marijuana consumption. Thus, the objective of the current article is (i) to 
summarize the most recent findings of the field; (ii) to highlight the putative therapeutic 
potential of targeting cannabinoid signaling; (iii) to identify open questions and key 
challenges; and (iv) to suggest promising future directions for cannabinoid-based drug 
development.
Keywords: cannabinoid signaling, endocannabinoid, inflammation, immune response, phytocannabinoid, multiple 
sclerosis, tumor immunology, marijuana
iNTRODUCTiON
The endocannabinoid System (eCS)  
and its Connections in a Nutshell
The ECS is a recently emerging, multifaceted signaling system, comprising various endogenous 
ligands [i.e., the “endocannabinoids” (eCBs), e.g., arachidonoylethanolamine (a.k.a. ananda-
mide, AEA), 2-arachidonoylglycerol (2-AG), etc.], eCB-responsive receptors (e.g., CB1 and CB2 
cannabinoid receptors, etc.), as well as enzymes and transporters involved in the synthesis 
FigURe 1 | Simplified overview of the endocannabinoid system.
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[e.g., N-acyl phosphatidylethanolamine-specific phospholip-
ase D (NAPE-PLD), diacylglycerol lipase-α and -β, protein 
tyro sine phosphatase non-receptor type 22 (PTPN22), etc.], 
cellular uptake/release [i.e., the putative endocannabinoid mem-
brane transporter (EMT)], intracellular transport (various fatty 
acid-binding proteins) and degradation [e.g., fatty acid amide 
hydrolase (FAAH), monoacylglycrol lipase, cyclooxygenase 2 
(COX2), etc.] of the eCBs (Figure 1) (1–10).
Moreover, in a wider sense, based on structural similarities 
and/or partial overlaps in the ligand affinities, many other 
receptors [e.g., the recently deorphanized metabotropic GPR18, 
GPR55, and GPR119, the intranuclear peroxisome proliferator-
activated receptors (PPARs), as well as several members of the 
transient receptor potential (TRP) ion channel superfamily] 
together with some of their endogenous ligands (e.g., palmitoy-
lethanolamide, oleoylethanolamine) can be classified as “ECS-
related” entities (Figure 1) (11–14).
Besides the high number of ligands and potential receptors, 
complexity of the cannabinoid signaling is further increased by 
two phenomena: (i) the often observed biased agonism (i.e., when 
the same receptor exhibits signaling preference among its possible 
second messenger pathways depending on the actual ligand) of the 
metabotropic cannabinoid recep tors (15, 16) and (ii) by their 
potential of forming heteromers either with each other, or with 
various other G protein-coupled receptors.
Indeed, CB1 is generally considered to signal through Gαi 
protein leading to a decrease in the intracellular cyclic adenosine 
monophosphate (cAMP) level, and activation of the β-arrestin 1 
and 2 pathways. On one hand, signaling bias can lie in the “choice” 
of the ligand in preferring (i.e., activating with higher relative 
efficiency) the β-arrestin pathway(s) over the G protein-coupled 
one or vice versa. On the other hand, in some cases coupling to 
Gαs, Gαq, or Gα12/13 proteins (leading to the elevation of cAMP level, 
activation of phospholipase C, or Rho pathway, respectively) 
was also observed, adding an extra layer of complexity to CB1 
signaling (Figure 2) (14–21). Importantly, similar to many other 
G protein-coupled receptors, biased signaling was described in 
case of CB2 or even in case of the “ECS-related” GPR18, GPR55, 
and GPR119 (14, 16, 19–22).
Moreover, without being exhaustive, CB1 was shown to form 
functional heteromers with, e.g., δ opioid receptor (DOR) (23), 
A2A adenosine receptor (24), D2 dopamine receptor (25), orexin-1 
receptor (26), etc., whereas CB2 was proven to heteromerize with, 
e.g., CXCR4 chemokine receptor (27), or GPR55 (28). On top 
of that, functional cooperation between CB1 and several recep-
tor tyrosine kinases was also observed [Figure  2; extensively 
reviewed in Ref. (19)].
Considering the above described complexity of the system, 
it is not surprising that, at least some parts of, the ECS is pre-
sent in virtually every cell type of the human body, and it was 
shown to be involved in the regulation of a plethora of physi-
ological processes. In the central nervous system (CNS), these 
processes include regulation of appetite, pain sensation, mood, 
and memory, whereas in the peripheral tissues, e.g., bone for-
mation, spermatogenesis, sebum production, etc., and, maybe 
most importantly, immune functions (7, 29–37). Indeed, eCB 
signaling was shown to be an important orchestrator of both the 
innate and adaptive immune responses. Although there are some 
FigURe 2 | “Classical” CB1 signaling (green) and beyond: examples for 
biased agonism and heteromerization. Note that besides the presented 
complexity, actual biological action of a given CB1 modulator may also depend 
on its capability to penetrate through the cell membrane. Theoretically, 
cell-penetrating agonists/antagonists (i.e., ones being capable to act on both 
the surface membrane and mitochondrial CB1) and their extracellularly 
restricted variants (i.e., ones targeting exclusively the surface membrane 
subset of CB1) may also exert differential biological actions; however, such 
comparisons remain to be performed in future targeted studies.
FigURe 3 | Overview of the most important potential targets of the pCBs. 
Note that there are more than 100 pCBs in Cannabis sativa, and each of 
them can be characterized by a unique “molecular fingerprint.” Obviously, 
every pCB is evidenced to interact with only a part of the potential targets 
presented on the figure. Moreover, the interactions can often lead to 
opposing molecular biology outcomes [e.g., THC is a partial CB1 agonist, 
whereas CBD is a CB1 antagonist/inverse agonist].
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contradictions in the literature, ECS is generally considered to 
be a homeostatic “gate-keeper” of the immune system, prevent-
ing the onset of pathological, overwhelming proinflammatory 
responses. For example, CB1 and CB2 double KO mice exhibited 
stronger allergic inflammation than wild-type mice. Importantly, 
these alterations were shown to be mediated via the pathologi-
cally increased chemokine release of epidermal keratinocytes, 
suggesting that lack of homeostatic eCB signaling skewed 
keratinocytes toward a proinflammatory phenotype. On the 
other hand, FAAH−/− mice (having elevated eCB levels) showed 
reduced allergic responses (29), further arguing for the concept 
that elevation of the eCB tone (e.g., by abrogating degradation 
of the eCBs or by directly activating cannabinoid receptors) 
usually leads to potent anti inflammatory/antiallergic actions 
[extensively reviewed in, e.g., Ref. (7, 30, 31, 33, 34, 36–41)].
Active Components of Cannabis sativa 
(Hemp)—Phytocannabinoids (pCBs)  
and Beyond
It is known since ancient times that consumption of different 
parts of the plant Cannabis sativa can lead to psychotropic 
effects. Moreover, mostly, but not exclusively because of its 
potent analgesic actions, it was considered to be beneficial in 
the management of several diseases (19, 42, 43). Nowadays it 
is a common knowledge that these effects were mediated by 
the complex mixture of biologically active substances produced 
by the plant. So far, at least 545 active compounds have been 
identified in it, among which, the best-studied ones are the 
so-called pCBs. It is also noteworthy that besides these com-
pounds, ca. 140 different terpenes [including the potent and 
selective CB2 agonist sesquiterpene β-caryophyllene (BCP) 
(44)], multiple flavonoids, alkanes, sugars, non-cannabinoid 
phenols, phenylpropanoids, steroids, fatty acids, and vari-
ous nitrogenous compounds (19, 45, 46) can be found in the 
plant, individual biological actions of which are mostly still 
nebulous. Among the so far identified >  100 pCBs (19, 47), 
the psychotropic (−)-trans-Δ9-tetrahydrocannabinol (THC) 
and the non-psychotropic (−)-cannabidiol (CBD) are the 
best-studied ones, exerting a wide-variety of biological actions 
[including but not exclusively: anticonvulsive, analgesic, 
antiemetic, and anti inflammatory effects, etc.; for extensive 
reviews, see e.g., Ref. (8, 19)]. Of great importance, pCBs have 
been shown to modulate the activity of a plethora of cellular 
targets, extending their impact far beyond the “classical” (see 
above) cannabinoid signaling. Indeed, besides being agonists 
[or in some cases even antagonists! (48)] of CB1 and CB2 can-
nabinoid receptors, some pCBs were shown to differentially 
modulate the activity of certain TRP channels, PPARs, seroto-
nin, α adrenergic, adenosine or opioid receptors, and to inhibit 
COX and lipoxygenase enzymes, FAAH, EMT, etc. (8, 19, 
48, 49). Moreover, from a clinical point-of-view, it should also 
be noted that pCBs can indirectly modify pharmacokinetics of 
multiple drugs (e.g., cyclosporine A) by interacting with several 
cytochrome P 450 (CYP) enzymes (50, 51). Taken together, 
pCBs can be considered as multitarget polypharmacons, each 
of them having unique “molecular fingerprints” created by the 
characteristic activation/inhibition pattern of its locally avail-
able cellular targets (Figure 3) (52).
SeLeCTeD ePiSODeS OF “(PHYTO)
CANNABiNOiD iMMUNOBiOLOgY”
As we briefly mentioned above, ECS is generally considered to be 
one of the “gate-keepers” of the immune system, preventing the 
onset of pathological immune responses [extensively reviewed 
in Ref. (7, 30, 31, 33, 34, 36–41)]. Considering that many of the 
aforementioned “non-classical” cannabinoid targets (e.g., TRP 
channels and PPARs) are also key regulators of the immune 
system (53–55), it is not surprising that both eCBs and pCBs can 
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deeply influence immune responses. Based on this, elevation of 
the eCB tone and/or application of pCBs augur to be beneficial 
in those conditions, when one needs to suppress potentially 
detrimental immune responses (e.g., in organ transplantation 
or autoimmune diseases, etc.). However, administration of such 
medications may hold the risk of suppressing desired immuno-
logical reactions against pathogens and tumor cells.
Since clinical administration of medical marijuana as well 
as of purified/synthetic pCBs is nowadays under increasing 
scrutiny, in the next chapters we intend to summarize the most 
important data of the field, and, while also highlighting existing 
controversies and limitations, to point toward possible future 
directions of cannabinoid-based medicines (Table 1).
Organ Transplantation
In order to improve quality of life and life expectancy, prevention 
of acute and chronic rejection following solid organ transplan-
tation, and avoidance of the development of graft-versus-host 
disease (GVHD) after bone marrow transplantation are key 
clinical challenges. Indeed, in order to overcome these problems, 
a number of different promising therapeutic opportunities are 
currently investigated, including, e.g., transplantation of tolero-
genic dendritic cells (DCs) (56), modulation of myeloid-derived 
suppressor cells (MDSCs) (57) or regulatory T cells (Treg) (58), 
as well as inhibition of Janus kinase signaling (59), etc. Due to 
their well-described anti inflammatory effects, pCBs are also 
potential candidates to improve therapeutic protocols of trans-
plantation (60).
The concept that positive modulation of cannabinoid signal-
ing could be helpful in transplantation is supported by multiple 
pieces of evidence. Indeed, recent findings showed that cardiac 
allograft rejection was accelerated in CB2−/− mice compared to 
wild-type recipients. In these experiments, bone marrow-derived 
dendritic cells (BM-DCs) of CB2−/− mice exhibited enhanced 
secretion of the proinflammatory cytokines interleukin (IL)-1β, 
IL-6, and tumor necrosis factor, as well as transforming growth 
factor-β1 upon Toll-like receptor (TLR) activation by lipopoly-
saccharide (LPS) or CpG. In addition, secretion of the Th1/
Th17-promoting IL-12 and IL-23 cytokines was also increased 
in CB2−/− BM-DCs, and CD4+ T  cells of the KO mice showed 
an enhanced capacity to differentiate into interferon (IFN)-γ- or 
IL-17-producing effector cells, altogether suggesting that CB2 
may be a potential therapeutic target in the clinical management 
of host-versus-graft reactions (61).
Importantly, not only CB2, but also CB1 emerged to be a 
promising therapeutic target in preventing organ rejection. 
Indeed, in mice, THC was recently found to attenuate host-
versus-graft response and delayed rejection of skin graft by 
(i) reducing T cell proliferation and activation in draining lymph 
nodes of the recipient mice and (ii) decreasing early stage rejec-
tion-indicator cytokines, including IL-2 and IFN-γ. Moreover, 
by employing selective antagonists, as well as CB1 and CB2 KO 
mice, the authors also showed that these effects were mediated 
via inducing MDSCs and activation of CB1 receptors (62).
Moreover, another study showed that, besides THC, CBD 
may also represent a promising novel treatment modality in 
organ transplantation (63), and administration of certain pCBs 
appeared to be promising in GVHD, too. Indeed, in an acute 
murine model of GVHD, THC (20  mg/kg i.p.) suppressed 
splenocyte transfer-induced weight loss, liver and intestinal 
tissue injury, as well as mortality. Importantly, THC treatment 
(i) reduced the expansion of donor-derived effector T  cells; 
(ii) blocked the killing of host-derived immune cells; (iii) pro-
moted Foxp3+ Treg cells; and (iv) normalized the impaired 
hematopoiesis seen during GVHD. The effects were thought 
to be CB1- and CB2-mediated ones, since both CB1 (AM251) 
and CB2 (SR144528) specific inverse agonists were able to par-
tially prevent the effect of THC in normalizing splenomegaly. 
Among them the CB2-selective SR144528 appeared to be more 
efficient, and the combination of the two inverse agonists could 
completely abrogate THC’s beneficial effects arguing for that tar-
geting CB1 and/or CB2 cannabinoid receptors may constitute a 
novel treatment modality against acute GVHD (64). Finally, data 
of a recent phase II clinical study (reference ID at clinicaltri-
als.gov: NCT01385124) showed that orally administered CBD 
(300 mg/day) is a safe and efficient way to improve the standard 
GVHD prophylaxis (65).
Autoimmune Diseases
The concept that dysregulation of the ECS can play a role in 
autoimmune diseases is supported by several lines of evidence. 
Indeed, the missense Arg → Trp (R620W) polymorphism of 
the eCB synthesizing enzyme PTPN22 [encoding lymphoid 
protein tyrosine phosphatase (LYP), which is important in 
negatively controlling activation of T lymphocytes] was found 
to be associated with increased risk of type 1 diabetes mellitus 
(T1DM), rheumatoid arthritis (RA), juvenile idiopathic arthri-
tis, systemic lupus erythematosus, Graves disease, myasthenia 
gravis, generalized vitiligo, and granulomatosis with polyangii-
tis [previously known as Wegener’s granulomatosis; reviewed 
in Ref. (66)]. Moreover, a common dinucleotide polymor-
phism of CB2, resulting in a Gln → Arg substitution (Q63R), 
which is accompanied by a reduced capability of CB2-mediated 
signaling to suppress T cell proliferation (67), was associated 
with an increased risk of immune thrombocytopenia (68), 
and celiac disease (69). In line with these data, cooccurrence 
of Q63R polymorphism and immune-mediated disorders in 
chronic hepatitis C virus (HCV) infection was also observed 
(70), whereas the healthy CB2 variant was associated with 
more severe inflammation and hepatocellular necrosis, most 
probably because the intact CB2 could more efficiently inhibit 
antiviral T cell functions (71). Thus, the concepts to positively 
modulate eCB tone, to activate CB2 receptor and to administer 
certain pCBs has already been suggested in, e.g., RA, T1DM, 
autoimmune myocarditis, ulcerative colitis, Crohn’s disease, 
etc. as well (63, 72–81), but so far, the “cannabinoid-wise” best 
explored autoimmune disease is unambiguously the multiple 
sclerosis (MS).
Indeed, AEA levels of the peripheral lymphocytes of MS 
patients was found to be elevated compared to healthy indi-
viduals, suggesting the development of a complex dysregula-
tion in the ECS of MS patients (82, 83). Moreover, TLR and 
cannabinoid receptor cross-talk (84), as well as novel, “ECS-
related” receptors (GPR18 and GPR55) have all been suggested 
TABLe 1 | Overview of the compounds mentioned in the manuscript.
Compound Model system Mechanism Phenomenon Reference
Receptors/
pathway
involved cell type/
tissue
AEA Human - Lymphocytes Elevation in MS patients (82, 83)
AEA TMEV CB1 TMEV-infected 
astrocytes
Increased IL-6 release (86)
2-AG Acute and chronic EAE ? M2 macrophages, 
lymphocytes
Direct and immune-mediated neuroprotection (88)
THC WT and CB1/2 KO mice CB1 T cells Delayed rejection of skin graft, reduced T cell proliferation,  
IL-2 and IFN-γ secretion
(62)
THC Murine acute GVHD model CB1 < CB2 Effector T cells, 
Foxp3+ Treg cells
Reduced weight loss, intestinal tissue injury and mortality (64)
THC Relapsing EAE in ABH mice ? ? Slower accummulation of disability (117)
THC 4T1 mammary carcinoma 
cell line
CB2 Complex actions Increased metastasis formation in vivo due to the inhibition  
of the antitumor immune response
(140)
THC C57Bl/6 mice CB1/CB2-
dependent and 
independent 
mechanisms
Splenocytes Enhanced HIV antigen-specific immune response (156)
THC Legionella pneumophila 
infection
CB1/CB2 T cells Th1 → Th2 shift (CB1: suppression of IL-12Rβ2; CB2: 
enhancement of GATA-3 upregulation)
(163)
CBD Mouse autoimmune 
myocarditis
Decreased 
oxidative/nitrative 
stress
T cells Attenuated CD3+ and CD4+ response, myocardial fibrosis  
and dysfunction
(63)
CBD Human phase II clinical trial 
(NCT01385124)
? ? Oral CBD improved standard GVHD prophylaxis (65)
CBD Relapsing EAE in ABH mice Voltage-gated 
Na+ channels
? Slower accumulation of disability (117)
CBD EAE ? T cells T cell exhaustion, decreased antigen presentation, 
antiproliferative, and antioxidant effects
(119)
CBD TMEV-induced demyelinating 
disease
A2A (?) (maybe via 
inhibiting ENT1?)
Endothelial cells, 
leukocytes
Decreased leukocyte transmigration (120, 123)
BCP EAE CB2 Microglia, CD4+  
and CD8+ T cells,  
Th1/Treg balance
Suppression of motor paralysis and neuroinflammation (102)
VCE-003 
(CBG-
derivative)
EAE CB2 and PPARγ T cells, macrophages Amelioration of neurological defects; inhibition of Th1/Th17 
cytokine/chemokine secretion, and M1 polarization
(101)
CB52 EAE CB1 Microglia, T cell, 
oligodendrocyte
Reduced microglia activation, nitrotyrosine formation, T cell 
infiltration, oligodendrocyte toxicity, myelin loss, and axonal 
damage in the mouse spinal cord white matter
(87)
Gp1a EAE CB2 Th1/Th17 Amelioration of EAE, reduction of Th17 differentiation (91)
Gp1a CLP CB2 Neutrophil 
granulocytes
Decreased neutrophil recruitment, but increased activation; 
decreased serum IL-6 level, bacteriemia and lung damage
(145)
R(+)
WIN55,212
Mouse Chagas disease 
model
CB1 (?) Cardiomyocytes Reduced invasion of cardiomyoblasts, increased 
parasitemia
(146)
SR144528 EAE CB2 antagonism Spinal cord, splenic 
mononuclear cells
Worsening of clinical severity (90)
SR144528 Experimental cerebral  
malaria (ECM)
CB2 antagonism CD11b+ macrophages 
and neutrophils (?)
Increased ECM resistance (147)
AM630 and 
JTE907
Mice CB2 inverse 
agonism
Acitvated lymph nodes Improved antigen-specific immune response (149)
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to play a role in the pathogenesis of MS (85), and CB1 (86–88), 
but especially CB2 also emerged as a remarkably powerful and 
multifaceted future therapeutic target in this disease (88–100).
In line with these data, daily administration of compound 
VCE-003 [a quinone derivative of the non-psychotropic 
pCB (−)-cannabigerol (CBG)] from day 6 postimmunization 
6Oláh et al. Immunological Roles of Cannabinoid Signaling
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for 21 days was able to ameliorate the neurological defects and 
the severity of experimental autoimmune encephalomyelitis 
(EAE; a murine model of MS) induced by subcutaneous immu-
nization with myelin oligodendrocyte glycoprotein (MOG35–55; 
300 µg) and Mycobacterium tuberculosis (200 µg) in a 1:1 mix 
with incomplete Freund’s adjuvant in mice. VCE-003 inhibited 
the secretion of Th1/Th17 cytokines and chemokines in primary 
murine T  cells and dampened the IL-17-induced, proinflam-
matory M1 polarization of macrophages in a CB2 and PPARγ-
dependent manner (101). In line with these data, BCP suppressed 
motor paralysis and neuroinflammation in EAE by inhibiting 
microglial cells, CD4+ and CD8+ T  lymphocytes, as well as 
protein expression of proinflammatory cytokines. Furthermore, 
it diminished axonal demyelination and modulated Th1/Treg 
immune balance through the activation of CB2 (102).
With respect to the “classical” pCBs, beneficial effects of 
Sativex® (a buccal spray, which contains THC and CBD in a 
1:1 ratio) and other pCB-based formulations in alleviating 
symptoms (e.g., spasticity, sleeping difficulty, neurogenic lower 
urinary tract dysfunction, gait, etc.) of MS are also well-described 
(103–111). However, since there are some controversies in the 
available data (112, 113), their long-term efficiency needs to be 
further investigated (108, 114). The necessity of such studies is 
further underscored by the findings of a recently conducted, 
small clinical trial, in which Bedrocan® (medical-grade cannabis, 
practically lacking CBD) was found to be effective in alleviating 
spasticity in 85% of Nabiximols (United States Adopted Name of 
Sativex®) non-responder patients (115), highlighting how deeply 
the exact composition of each pCB-based medication can influ-
ence the clinical efficacy.
Importantly, a growing body of evidence supports the 
concept that, besides providing symptomatic relief, treatment 
with appropriately selected pCBs may even have therapeutic 
value in MS. Indeed, an early study demonstrated that in EAE, 
THC-treated animals had either no or mild clinical symptoms 
with a survival greater than 95%, whereas more than 98% of 
the animals died in the placebo group. The better survival was 
accompanied by a marked reduction of inflammation in the 
CNS of THC-treated animals (116). Partially in line with these 
data, in a 3-year, phase III clinical trial (albeit the authors did 
not detect a beneficial effect of oral THC in progressive MS in 
general) a thorough subgroup analysis of people with less dis-
ability and more rapid progression demonstrated a significant 
deceleration of disease development in the oral THC group 
compared to placebo (117).
In another study, synthetic CBD could slow down the accu-
mulation of disability from the inflammatory penumbra during 
relapsing EAE in ABH mice, possibly via blocking voltage- 
gated Na+ channels. In addition, non-sedating doses of THC 
dose-dependently inhibited the accumulation of disability dur-
ing EAE (117). According to another EAE study, in which CBD 
was applied after the development of the disease, CBD (10 mg/kg 
mouse, i.p.) reversed EAE-induced downregulation of the phos-
phoinositide 3-kinase, protein kinase B (Akt), and mammalian/
mechanistic target of rapamycin (mTOR) in the spinal cord. 
Moreover, CBD increased brain-derived neurotrophic factor 
level, downregulated IFN-γ and IL-17, upregulated PPARγ, 
and was found to promote neuronal survival by inhibiting 
c-Jun N-terminal kinase and p38 mitogen-activated protein 
kinase (118). Furthermore, another group demonstrated that 
in EAE, CBD exerted its immunoregulatory effects in activated 
MOG35–55-specific memory T cell cells via (i) suppressing pro-
inflammatory Th17-related transcription; (ii) promoting T cell 
exhaustion/tolerance; (iii) enhancing IFN-dependent antipro-
liferative program; (iv) hampering antigen presentation; and 
(v) inducing antioxidant milieu resolving inflammation (119).
In line with the above data, CBD was found to be protective 
in Theiler’s encephalomyelitis virus (TMEV)-induced demyeli-
nating disease (a viral model of MS) via activating A2A recep tors 
(120). It is noteworthy that although A2A receptor most prob-
ably does not bind CBD, the phenomenon that it can mediate 
anti inflammatory actions of this pCB is not unprecedented. 
Indeed, similar effects were shown in murine acute lung injury 
model (121) and in human sebocytes (122) too, and they 
were thought to be realized via the inhibition of equilibrative 
nucleoside transporter(s) (e.g., ENT1, which mediates adenosine 
uptake of the cells) and the subsequently elevated “adenosine 
tone” (123).
Tumor immunology
Besides that medical marijuana is increasingly used in various 
tumors as a palliative treatment option (124), exploitation of the 
putative antitumor therapeutic potential of the endo- and pCBs 
is a hot topic of today’s cannabinoid research. Via activating CB1, 
CB2, or other cellular targets, both endo- and pCBs were already 
convincingly shown to exert complex [e.g., antiproliferative and 
proapoptotic effects, inhibition of angiogenesis, inhibition of 
tumor cell chemotaxis via activating CB2/CXCR4 heteromers, 
etc. (27, 125–134)] antitumor effects in most of the test systems 
in vitro. Although there are some exceptions [e.g., engagement 
of CB1 and CB2 were found to promote tumor progression in 
human melanoma cells (CB1), in renal cell carcinoma (CB1), as 
well as in colon cancer (CB2) (135–137)], most studies agree 
that their putative beneficial antitumor effects deserves further 
scrutiny (138, 139). However, several lines of evidence argue 
for that promising in vitro antitumor data cannot necessarily be 
translated to in vivo clinical benefits, because of the cannabinoid-
mediated suppression of the antitumor (Th1-dominated) 
immune response (138, 139). Indeed, by investigating human 
(MCF-7 and MDA-MB-231) and mouse (4T1) mammary carci-
noma cell lines expressing low to undetectable levels of CB1 and 
CB2, McKallip et al. found that these cells were not only resistant 
to THC-induced cytotoxicity, but THC treatment led to elevated 
4T1 tumor growth and metastasis due to CB2-mediated inhibi-
tion of the antitumor immune response (140). Thus, although the 
very few available human studies [reviewed in Ref. (139)] sug-
gest that THC and cannabis-extracts may have some beneficial 
effects beyond mere palliation, well-controlled, further studies 
are invited to find the most appropriate place of cannabinoid 
medications in the antitumoral therapeutic repertoire.
Defense against Pathogens
Theoretically, administration of endo- and pCBs may hold the 
risk of dampening appropriate immune responses, and thereby 
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increasing susceptibility toward infectious diseases. However, 
in light of the literature data, the situation appears to be more 
complex. Indeed, certain control over the overwhelming inflam-
matory processes in, e.g., systemic inflammatory response 
syndrome or sepsis would be undoubtedly highly desirable 
(141–143). Within the “classical” ECS, the anti inflammatory 
CB2 appears to be the most promising candidate to adjust such 
immune responses, but recently other receptors (e.g., CB1 or the 
apparently rather proinflammatory GPR55) were also proven 
to be potent and relevant regulators. The available (some-
what controversial) data about the roles of these receptors in 
sepsis, and especially the possible therapeutic exploitation of 
GPR55-antagonism in such conditions, is extensively reviewed 
in Ref. (34).
With respect to CB2, it has recently been shown that loss 
of homeostatic CB2 signaling worsened LPS-induced sepsis 
in mice, whereas activation of CB2 was proven to be beneficial 
via reducing leukocyte endothelial interactions, and thereby 
preventing further inflammatory damage (144). Similarly, in a 
cecal ligation and puncture (CLP) model of sepsis, CB2−/− mice 
exhibited higher serum IL-6 levels and bacteremia, and had 
decreased survival rates, whereas CB2 agonism increased the 
mean survival time in wild-type mice (145). Furthermore, in 
a mice model of Trypanosoma cruzi infection (Chagas disease) 
it was shown that the non-specific CB receptor agonist R(+)
WIN55,212 significantly reduced cardiac inflammation. How-
ever, it also led to considerably increased parasitemia, therefore 
therapeutic value of such non-specific drugs remained ques-
tionable (146).
In contrast to the aforementioned findings, in a mice model 
of cerebral malaria (a severe and often fatal complication of 
Plasmodium falciparum infection), CB2 antagonism, as well 
as the CB2−/− genotype were protective, and led to enhanced 
survival and a diminished blood-brain barrier disruption (147). 
Moreover, CB2−/− (but not CB1−/−) mice were resistant to LPS-
driven suppression of serum progesterone levels and preterm 
birth (148). Last, but not least, transient administration of the 
CB2 inverse agonists AM630 (10 mg/kg) or JTE907 (3 mg/kg) 
during immunization was found to improve antigen-specific 
immune responses in young and aged mice through the upregu-
lation of immunomodulatory genes in secondary lymphoid 
tissues (149).
Thus, in light of the above data, it seems to be highly likely 
that both enhancement and suppression of the eCB signaling 
might have therapeutic value in carefully selected clinical 
conditions, which already suggests that administration of pCBs 
and/or other cannabis-derivatives is also not without contro-
versies. Indeed, although several pCBs were shown to exert 
potent direct antibacterial activity (150), their aforementioned 
immunosuppressive effects definitely limit their therapeutic 
administration in infections. Since excellent overviews of the 
effects of pCBs and the ECS in viral (151), and other infections 
(34) were published recently, here we will only highlight some 
of the most interesting controversies of the field.
Without being exhaustive, in a Wistar rat model of pneumo-
coccal meningitis, CBD (10 mg/kg, i.p.) reduced host immune 
response, and prevented cognitive impairments (152). Chronic 
administration of THC induced intestinal anti-inflammatory 
miRNA expression during acute Simian Immunodeficiency 
Virus (SIV) infection of rhesus macaques (153), and did not 
increase viral load in brain tissue (154). Likewise, another 
study also showed that chronic THC administration did not 
increase viral load or aggravate morbidity; in contrast, it could 
actually ameliorate SIV disease progression, via retention of 
body mass, and attenuation of inflammation (155). Moreover, 
it was also shown that under certain conditions, THC could 
even enhance Human Immunodeficiency Virus (HIV) antigen-
specific immune responses, which occurred through both CB1/
CB2-dependent and -independent mechanisms (156), and find-
ings showed no evidence for a negative effect of cannabis use 
on circulating CD4+ T  cell counts/percentages in HCV-HIV 
coinfected patients (157). Thus, it is not surprising that medical 
marijuana is part of HIV/AIDS adjuvant treatment in several 
countries (158).
With respect to other infections, it is noteworthy that CBD 
was recently suggested to be explored as a treatment for indi-
viduals suffering from post-Ebola syndrome (159). Moreover, 
although it had no effect on Hepatitis B Virus, 10  µM CBD 
inhibited HCV replication by 86.4% in vitro (160). Finally, CBD 
(30 mg/kg/day, i.p.) increased survival, and promoted rescue of 
cognitive function in a murine model of cerebral malaria (161).
Despite these promising findings, data of some other stud-
ies argue against the administration of pCBs in infectious 
diseases. Indeed, chronic THC treatment decreased the efficacy 
of the memory immune response to Candida infection (162). 
In Legionella pneumophila infection, THC treatment prior 
to contamination induced a shift from Th1 to Th2 immunity 
in a CB1 and CB2 dependent manner (163). Moreover, THC 
impaired the inflammatory response to influenza infection 
(164), suppressed immune function, and enhanced HIV 
replication in a mice model, where human peripheral blood 
leukocytes (PBLs) were implanted into severe combined immu-
nodeficient mice (huPBL-SCID mice) (165). Interestingly, 
investigation of plasmocytoid dendritic cells (pDCs) revealed 
an intriguing functional heterogeneity of the pCBs, i.e., THC 
(but not CBD!) suppressed secretion of IFN-α by pDC from 
both healthy and HIV+ donors, arguing for that although THC 
may impair antiviral responses, but this may also be protective 
in neuroinflammation associated with prolonged HIV infec-
tion (166). Taken together, these data suggest that although 
cannabinoid signaling may decrease the efficiency of certain 
antipathogen immune responses, in some cases it might still 
be beneficial by limiting overwhelming inflammatory response 
and tissue destruction. Further studies are therefore invited 
to determine and exploit exact therapeutic value of eCBs and 
pCBs in such diseases.
COMPLeX iMMUNOLOgiCAL eFFeCTS 
OF MeDiCAL AND “ReCReATiONAL” 
MARiJUANA CONSUMPTiON
Considering the wide-spread popularity of marijuana con-
sumption and the social debate about its legislative status, it 
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is clear that there is an emerging demand from the scientific 
community, the society, as well as from the decision makers 
to design further in vitro and in vivo studies to better charac-
terize biological actions and potential risks of marijuana and 
other cannabis derivatives. This is especially urging since even 
habitual exposure to THC appears to be capable of impacting 
on human cell-mediated immunity and host defense (167). 
Moreover, recent animal studies showed that parental or 
prenatal exposure to cannabis could trigger epigenetic changes 
that led to significant transgenerational immunological con-
sequences (168). Indeed, perinatal exposure of mice to THC 
was found to trigger profound T  cell dysfunction, thereby 
suggesting that children of marijuana abusers who have been 
exposed to THC in utero, may be at a higher risk of exhibit-
ing immune dysfunction and contracting infectious diseases 
including HIV infection (169). Following up the line of the 
possible long-term consequences of marijuana consumption, 
it is important to note that although acute THC exposure in 
adolescent mice is anti inflammatory, it also has long-lasting 
proinflammatory effects on brain cytokines, and this modula-
tion may affect vulnerability to immune and behavioral diseases 
in adulthood (170, 171).
Intriguingly, in spite of the above data, in an early double-
blind, placebo-controlled human study no endocrine or immu-
nological alterations were observed upon THC use (172). How ever, 
a more recent study, which aimed to assess the effects of medical 
cannabis ingestion on peripheral blood mononuclear cells, 
revealed an immunosuppressive effect of cannabinoid prepara-
tions via deactivation of signaling through the proinflammatory 
p38 MAP kinase and mTOR pathways and a concomitant 
deactivation of the promitogenic p42/p44 extracellular signal-
regulated kinase (ERK)-1/2 signaling. However, it should also be 
noted that long-term cannabis exposure in two patients resulted 
in reversal of this effect (173). Similar to these data, a significant 
decrease in serum immunoglobulin (IgG and IgM) levels, in C3 
and C4 complement protein concentrations, as well as in abso-
lute numbers of T and B lymphocytes and natural killer (NK) 
cells was observed in bhang (an edible form of cannabis) users 
as compared to controls. Interestingly, FAAH (the major eCB-
degrading enzyme) expression also showed significant decrease 
in lymphocytes of these subjects (174).
OPeN QUeSTiONS, FUTURe 
CHALLeNgeS, AND PeRSPeCTiveS
Although research efforts of the last three decades provided an 
extremely large (and ever increasing) body of evidence, there 
are still significant gaps in our understanding with respect to the 
cannabinoid signaling, and its optimal therapeutic exploitation, 
inviting obviously a number of specific complementary in vitro, 
in vivo and clinical studies. Along these lines, several important 
challenges should be faced and handled.
Potential Side effects
From the point-of-view of future drug development, the most 
obvious challenge is to avoid potential psychotropic and cardiac 
side effects, as well as development of tolerance and dependence 
due to activation of CB1 [overviewed in Ref. (8)]. Moreover, 
administration of THC and activation of CB1 were shown to lead 
to memory impairment, most probably due to the activation of 
the recently discovered, mitochondrially expressed subset of the 
receptor (175, 176), suggesting that extracellularly restricted 
CB1 agonists may be devoid of such side effects. Development 
of such compounds can therefore be a promising future 
direction in cannabinoid-based experimental pharmacology. 
Interestingly, however, it should also be noted that memory-
impairing effect of CB1 activation appears to be age-dependent; 
in fact, THC CB1-dependently improved memory function in 
aged mice (177). Furthermore, by using CB1−/− mice, it has also 
been demonstrated that lack of homeostatic CB1 signaling leads 
to a premature decline in cognitive abilities (178), and chronic 
THC administration-induced dramatic and sustained down-
regulation of CB1 was also suggested to play a role in cannabis-
induced cognitive dysfunction (179). Altogether, these data 
clearly indicate that memory problems can occur on the basis 
of both overactivation and critical impairment of CB1 signaling. 
Considering the aforementioned, somewhat confusing data, 
focused studies are definitely required to exclude potential 
memory-impairing side effects of any future brain-penetrating 
CB1 agonists before their clinical administration.
On the other hand, we should also keep in mind that antago-
nism/inverse agonism of CB1 located in the CNS can also lead 
to serious neuropsychiatric side effects (including suicide), as 
it became evidenced by the infamous, brain-penetrating CB1 
inverse agonist rimonabant (SR141716; trade names: Acomplia 
and Zimulti), which was applied as a potent anorexigenic agent 
for a few years in Europe, but was then retracted from the 
market (180). Fortunately, keeping CB1 modulators out from 
the CNS can relatively easily be solved by designing peripher-
ally restricted molecules, which cannot penetrate through the 
blood-brain barrier.
It should also be mentioned that in a recent phase 1 trial 
administration of a FAAH-inhibitor named “BIA 10-2474” led 
to the death of one volunteer and produced mild-to-severe 
neurological symptoms in four others (181, 182). Importantly, 
it has been proven that BIA 10-2474 was a very unspecific, 
promiscuous lipase inhibitor, and that fatal side effects most 
probably developed due to a complex metabolic dysregulation 
in the CNS caused by the inhibition of some of its off-targets, 
which underscores the importance of rigorous preclinical test-
ing of any drug candidates which are planned to be applied in 
human studies.
variable Composition of Cannabis-
Derivatives, impact of Cannabis  
Use History of the Patients
Clinical efficiency of complex cannabis-derivatives may greatly 
depend on their exact composition (115), since beyond the pCBs 
(each of which already possesses remarkably complex, unique 
molecular fingerprint), they contain many other biologically 
active, non-pCB components as well. Therefore, it is crucially 
important to describe biological actions and identify cellular 
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targets of these so far neglected components in well-controlled 
future studies.
Unfortunately, rigorous assessment of pCBs’ clinical efficiency 
is complicated by several factors. Indeed, in a recent study, Scott 
et  al. found that the combination of THC and CBD was more 
effective in killing HL60 leukemia cells than the individually 
applied pCBs. Even more importantly, using cannabinoids after 
the chemotherapy resulted in greater induction of apoptosis 
(183), highlighting that even the schedule of administration may 
influence the measured efficiency.
Another important issue which should be kept in mind while 
interpreting results of studies involving cannabis users is how 
well-controlled and reliable those prospective and retrospec-
tive human studies are. First, self-admission about the history 
of marijuana consumption may be misguiding. Second, due to 
the aforementioned “transgenerational” effects (168–171), in 
an “ideal” clinical study, inclusion/exclusion criteria should also 
consider “family history” of marijuana consumption. Third, 
purity/quality of the self-administered marijuana, as well as 
exposure to other illicit drugs, to alcohol (184), or to drugs 
belon ging to the “gray zone,” e.g., novel psychoactive substances 
[NPS, a.k.a. “designer drugs”; synthetic, psychoactive substances 
that are generally not (yet) under international regulatory 
control, and among which several synthetic cannabinoids are 
now present at the black market (185)] should also be explored, 
since these all can deeply influence immunological effects of 
acutely applied pCBs, thereby falsifying the results [e.g., acute 
application of pCBs was found to significantly inhibit both the 
basal and C-C motif chemokine ligand 2 (CCL2)-stimulated 
migration of monocytes, but only in individuals non-naive to 
Cannabis (186)].
CONCLUDiNg ReMARKS—LeSSONS  
TO LeARN FROM Cannabis
Research efforts of the past few decades have unambiguously 
evidenced that ECS is one of the central orchestrators of both 
innate and adaptive immune systems, and that pure pCBs as 
well as complex cannabis-derivatives can also deeply influence 
immune responses. Although, many open questions await to 
be answered, pharmacological modulation of the (endo)can-
nabinoid signaling, and restoration of the homeostatic eCB 
tone of the tissues augur to be very promising future directions 
in the management of several pathological inflammation-
accompanied diseases. Moreover, in depth analysis of the (quite 
complex) mechanism-of-action of the most promising pCBs is 
likely to shed light to previously unknown immune regulatory 
mechanisms and can therefore pave new “high”-ways toward 
developing completely novel classes of therapeutic agents to 
manage a wide-variety of diseases.
AUTHOR CONTRiBUTiONS
All authors wrote, edited, and approved the final version of this 
manuscript.
FUNDiNg
Preparation of this manuscript was supported by Hungarian 
(NRDIO 120552, 121360, and 125055), as well as EU (GINOP-
2.3.2-15-2016-00050) research grants. AO’s work was supported 
by the János Bolyai Research Scholarship of the Hungarian 
Academy of Sciences.
ReFeReNCeS
1. Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, 
Elphick MR, et al. International Union of Basic and Clinical Pharmacology. 
LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. 
Pharmacol Rev (2010) 62:588–631. doi:10.1124/pr.110.003004 
2. Păunescu H, Coman OA, Coman L, Ghiţă I, Georgescu SR, Drăghia F, 
et  al. Cannabinoid system and cyclooxygenases inhibitors. J Med Life  
(2011) 4:11–20. 
3. Chicca A, Marazzi J, Nicolussi S, Gertsch J. Evidence for bidirectional 
endocannabinoid transport across cell membranes. J Biol Chem (2012) 
287:34660–82. doi:10.1074/jbc.M112.373241 
4. Abood ME, Sorensen RG, Stella N, editors. endoCANNABINOIDS. New 
York, NY: Springer (2013). Available from: http://link.springer.com/10. 
1007/978-1-4614-4669-9
5. Kaczocha M, Rebecchi MJ, Ralph BP, Teng Y-HG, Berger WT, 
Galbavy W, et al. Inhibition of fatty acid binding proteins elevates brain 
anandamide levels and produces analgesia. PLoS One (2014) 9:e94200. 
doi:10.1371/journal.pone.0094200 
6. Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation 
by phytocannabinoids. Neurotherapeutics (2015) 12:692–8. doi:10.1007/
s13311-015-0374-6 
7. Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, Di Marzo V, et  al. 
Endocannabinoid signaling at the periphery: 50 years after THC. Trends 
Pharmacol Sci (2015) 36:277–96. doi:10.1016/j.tips.2015.02.008 
8. Ligresti A, De Petrocellis L, Di Marzo V. From phytocannabinoids to 
cannabinoid receptors and endocannabinoids: pleiotropic physiological 
and pathological roles through complex pharmacology. Physiol Rev (2016) 
96:1593–659. doi:10.1152/physrev.00002.2016 
9. Chicca A, Nicolussi S, Bartholomäus R, Blunder M, Aparisi Rey A, 
Petrucci V, et al. Chemical probes to potently and selectively inhibit endocan-
nabinoid cellular reuptake. Proc Natl Acad Sci U S A (2017) 114:E5006–15. 
doi:10.1073/pnas.1704065114 
10. Maccarrone M. Metabolism of the endocannabinoid anandamide: open 
questions after 25 years. Front Mol Neurosci (2017) 10:166. doi:10.3389/
fnmol.2017.00166 
11. Godlewski G, Offertáler L, Wagner JA, Kunos G. Receptors for acyletha-
nolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat (2009) 
89:105–11. doi:10.1016/j.prostaglandins.2009.07.001 
12. Caterina MJ. TRP channel cannabinoid receptors in skin sensation, 
homeostasis, and inflammation. ACS Chem Neurosci (2014) 5:1107–16. 
doi:10.1021/cn5000919 
13. O’Sullivan SE. An update on PPAR activation by cannabinoids. Br J Phar-
macol (2016) 173:1899–910. doi:10.1111/bph.13497 
14. Laprairie RB, Bagher AM, Denovan-Wright EM. Cannabinoid receptor 
ligand bias: implications in the central nervous system. Curr Opin Pharmacol 
(2017) 32:32–43. doi:10.1016/j.coph.2016.10.005 
15. Ibsen MS, Connor M, Glass M. Cannabinoid CB1 and CB2 receptor sig-
naling and bias. Cannabis Cannabinoid Res (2017) 2:48–60. doi:10.1089/
can.2016.0037 
16. Soethoudt M, Grether U, Fingerle J, Grim TW, Fezza F, de Petrocellis L, 
et  al. Cannabinoid CB2 receptor ligand profiling reveals biased signal-
ling and off-target activity. Nat Commun (2017) 8:13958. doi:10.1038/ 
ncomms13958 
17. Nogueras-Ortiz C, Yudowski GA. The multiple waves of cannabinoid 1 recep-
tor signaling. Mol Pharmacol (2016) 90:620–6. doi:10.1124/mol.116.104539 
18. Ford BM, Franks LN, Tai S, Fantegrossi WE, Stahl EL, Berquist MD, 
et  al. Characterization of structurally novel G protein biased CB1 
10
Oláh et al. Immunological Roles of Cannabinoid Signaling
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1487
agonists: implications for drug development. Pharmacol Res (2017) 
125:161–77. doi:10.1016/j.phrs.2017.08.008 
19. Solymosi K, Köfalvi A. Cannabis: a treasure trove or pandora’s box?  
Mini Rev Med Chem (2017) 17:1223–91. doi:10.2174/1389557516666161
004162133 
20. Mallipeddi S, Janero DR, Zvonok N, Makriyannis A. Functional 
selectivity at G-protein coupled receptors: advancing cannabinoid recep-
tors as drug targets. Biochem Pharmacol (2017) 128:1–11. doi:10.1016/j.
bcp.2016.11.014 
21. Priestley R, Glass M, Kendall D. Functional selectivity at cannabi noid 
receptors. Adv Pharmacol (2017) 80:207–21. doi:10.1016/bs.apha.2017. 
03.005 
22. Hassing HA, Fares S, Larsen O, Pad H, Hauge M, Jones RM, et  al.  
Biased signaling of lipids and allosteric actions of synthetic molecules for 
GPR119. Biochem Pharmacol (2016) 119:66–75. doi:10.1016/j.bcp.2016. 
08.018 
23. Rozenfeld R, Bushlin I, Gomes I, Tzavaras N, Gupta A, Neves S, et  al.  
Receptor heteromerization expands the repertoire of cannabinoid signal-
ing in rodent neurons. PLoS One (2012) 7:e29239. doi:10.1371/journal.
pone.0029239 
24. Lazzerini PE, Natale M, Gianchecchi E, Capecchi PL, Montilli C, 
Zimbone S, et  al. Adenosine A2A receptor activation stimulates collagen 
production in sclerodermic dermal fibroblasts either directly and through a 
cross-talk with the cannabinoid system. J Mol Med (Berl) (2012) 90:331–42. 
doi:10.1007/s00109-011-0824-5 
25. Bagher AM, Laprairie RB, Toguri JT, Kelly MEM, Denovan-Wright EM. 
Bidirectional allosteric interactions between cannabinoid receptor 1 (CB1) 
and dopamine receptor 2 long (D2L) heterotetramers. Eur J Pharmacol 
(2017) 813:66–83. doi:10.1016/j.ejphar.2017.07.034 
26. Ward RJ, Pediani JD, Milligan G. Heteromultimerization of cannabinoid 
CB(1) receptor and orexin OX(1) receptor generates a unique complex 
in which both protomers are regulated by orexin A. J Biol Chem (2011) 
286:37414–28. doi:10.1074/jbc.M111.287649 
27. Coke CJ, Scarlett KA, Chetram MA, Jones KJ, Sandifer BJ, Davis AS, 
et  al. Simultaneous activation of induced heterodimerization between 
CXCR4 chemokine receptor and cannabinoid receptor 2 (CB2) reveal a 
mechanism for regulation of tumor progression. J Biol Chem (2016) 291: 
9991–10005. doi:10.1074/jbc.M115.712661 
28. Balenga NA, Martínez-Pinilla E, Kargl J, Schröder R, Peinhaupt M, 
Platzer W, et al. Heteromerization of GPR55 and cannabinoid CB2 receptors 
modulates signalling. Br J Pharmacol (2014) 171:5387–406. doi:10.1111/
bph.12850 
29. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, 
et al. Attenuation of allergic contact dermatitis through the endocannabinoid 
system. Science (2007) 316:1494–7. doi:10.1126/science.1142265 
30. Chiurchiù V, Battistini L, Maccarrone M. Endocannabinoid signaling in 
innate and adaptive immunity. Immunology (2015) 144:352–64. doi:10.1111/
imm.12441 
31. Chiurchiù V. Endocannabinoids and immunity. Cannabis Cannabinoid 
Res (2016) 1:59–66. doi:10.1089/can.2016.0002 
32. Oláh A, Ambrus L, Nicolussi S, Gertsch J, Tubak V, Kemény L, et  al.  
Inhibition of fatty acid amide hydrolase exerts cutaneous anti-inflammatory 
effects both in vitro and in vivo. Exp Dermatol (2016) 25:328–30. doi:10.1111/
exd.12930 
33. Oláh A, Bíró T. Targeting cutaneous cannabinoid signaling in inflamma-
tion – a “high”-way to heal? EBioMedicine (2017) 16:3–5. doi:10.1016/j.
ebiom.2017.01.003 
34. Zhou J, Burkovskiy I, Yang H, Sardinha J, Lehmann C. CB2 and GPR55 
receptors as therapeutic targets for systemic immune dysregulation. Front 
Pharmacol (2016) 7:264. doi:10.3389/fphar.2016.00264 
35. Lu Y, Anderson HD. Cannabinoid signaling in health and disease. Can 
J Physiol Pharmacol (2017) 95:311–27. doi:10.1139/cjpp-2016-0346 
36. McCoy KL. Interaction between cannabinoid system and toll-like recep-
tors controls inflammation. Mediators Inflamm (2016) 2016:5831315. 
doi:10.1155/2016/5831315 
37. Cabral GA, Rogers TJ, Lichtman AH. Turning over a new leaf: cannabinoid 
and endocannabinoid modulation of immune function. J Neuroimmune 
Pharmacol (2015) 10:193–203. doi:10.1007/s11481-015-9615-z 
38. Chiurchiù V, Leuti A, Maccarrone M. Cannabinoid signaling and neu-
roinflammatory diseases: a melting pot for the regulation of brain immune 
responses. J Neuroimmune Pharmacol (2015) 10:268–80. doi:10.1007/
s11481-015-9584-2 
39. Cabral GA, Ferreira GA, Jamerson MJ. Endocannabinoids and the immune 
system in health and disease. Handb Exp Pharmacol (2015) 231:185–211. 
doi:10.1007/978-3-319-20825-1_6 
40. Bíró T, Tóth BI, Haskó G, Paus R, Pacher P. The endocannabinoid system 
of the skin in health and disease: novel perspectives and therapeutic oppor-
tunities. Trends Pharmacol Sci (2009) 30:411–20. doi:10.1016/j.tips.2009. 
05.004 
41. Acharya N, Penukonda S, Shcheglova T, Hagymasi AT, Basu S, 
Srivastava PK. Endocannabinoid system acts as a regulator of immune 
homeostasis in the gut. Proc Natl Acad Sci U S A (2017) 114:5005–10. 
doi:10.1073/pnas.1612177114 
42. Butrica JL. The medical use of Cannabis among the Greeks and Romans. 
J Cannabis Ther (2002) 2:51–70. doi:10.1300/J175v02n02_04 
43. Russo EB. Beyond Cannabis: plants and the endocannabinoid system. 
Trends Pharmacol Sci (2016) 37:594–605. doi:10.1016/j.tips.2016.04.005 
44. Gertsch J, Leonti M, Raduner S, Racz I, Chen J-Z, Xie X-Q, et  al.  
Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A (2008) 
105:9099–104. doi:10.1073/pnas.0803601105 
45. Elsohly MA, Slade D. Chemical constituents of marijuana: the complex 
mixture of natural cannabinoids. Life Sci (2005) 78:539–48. doi:10.1016/j.
lfs.2005.09.011 
46. Gertsch J, Pertwee RG, Di Marzo V. Phytocannabinoids beyond the Cannabis  
plant – do they exist? Br J Pharmacol (2010) 160:523–9. doi:10.1111/j. 
1476-5381.2010.00745.x 
47. Russo EB. Taming THC: potential Cannabis synergy and phytocannabi-
noid-terpenoid entourage effects. Br J Pharmacol (2011) 163:1344–64. 
doi:10.1111/j.1476-5381.2011.01238.x 
48. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three 
plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9- 
tetrahydrocannabivarin. Br J Pharmacol (2008) 153:199–215. doi:10.1038/
sj.bjp.0707442 
49. Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG. Evi dence 
that the plant cannabinoid cannabigerol is a highly potent alpha2- 
adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. 
Br J Pharmacol (2010) 159:129–41. doi:10.1111/j.1476-5381.2009.00515.x 
50. Zendulka O, Dovrtělová G, Nosková K, Turjap M, Šulcová A, Hanuš L, 
et  al. Cannabinoids and cytochrome P450 interactions. Curr Drug Metab 
(2016) 17:206–26. doi:10.2174/1389200217666151210142051 
51. Colombo D, Lunardon L, Bellia G. Cyclosporine and herbal supplement 
interactions. J Toxicol (2014) 2014:145325. doi:10.1155/2014/145325 
52. Brodie JS, Di Marzo V, Guy GW. Polypharmacology shakes hands with com-
plex aetiopathology. Trends Pharmacol Sci (2015) 36:802–21. doi:10.1016/j.
tips.2015.08.010 
53. Santoni G, Cardinali C, Morelli MB, Santoni M, Nabissi M, Amantini C. 
Danger- and pathogen-associated molecular patterns recognition by 
pattern-recognition receptors and ion channels of the transient receptor 
potential family triggers the inflammasome activation in immune cells and 
sensory neurons. J Neuroinflammation (2015) 12:21. doi:10.1186/s12974- 
015-0239-2 
54. Parenti A, De Logu F, Geppetti P, Benemei S. What is the evidence for the 
role of TRP channels in inflammatory and immune cells? Br J Pharmacol 
(2016) 173:953–69. doi:10.1111/bph.13392 
55. O’Sullivan SE, Kendall DA. Cannabinoid activation of peroxisome prolifer-
ator-activated receptors: potential for modulation of inflammatory disease. 
Immunobiology (2010) 215:611–6. doi:10.1016/j.imbio.2009.09.007 
56. Moreau A, Alliot-Licht B, Cuturi M-C, Blancho G. Tolerogenic dendritic cell 
therapy in organ transplantation. Transpl Int (2017) 30:754–64. doi:10.1111/
tri.12889 
57. Zhang C, Wang S, Yang C, Rong R. The crosstalk between myeloid derived 
suppressor cells and immune cells: to establish immune tolerance in 
transplantation. J Immunol Res (2016) 2016:4986797. doi:10.1155/2016/ 
4986797 
58. Romano M, Tung SL, Smyth LA, Lombardi G. Treg therapy in transplanta-
tion: a general overview. Transpl Int (2017) 30:745–53. doi:10.1111/tri.12909 
11
Oláh et al. Immunological Roles of Cannabinoid Signaling
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1487
59. Moore CA, Iasella CJ, Venkataramanan R, Lakkis FG, Smith RB, McDyer JF, 
et al. Janus kinase inhibition for immunosuppression in solid organ trans-
plantation: is there a role in complex immunologic challenges? Hum Immunol 
(2017) 78:64–71. doi:10.1016/j.humimm.2016.12.005 
60. Nagarkatti M, Rieder SA, Hegde VL, Kanada S, Nagarkatti P. Do 
cannabinoids have a therapeutic role in transplantation? Trends Pharmacol 
Sci (2010) 31:345–50. doi:10.1016/j.tips.2010.05.006 
61. Kemter AM, Scheu S, Hüser N, Ruland C, Schumak B, Findeiß M, et  al.  
The cannabinoid receptor 2 is involved in acute rejection of cardiac allografts. 
Life Sci (2015) 138:29–34. doi:10.1016/j.lfs.2015.02.012 
62. Sido JM, Nagarkatti PS, Nagarkatti M. Δ9-Tetrahydrocannabinol attenu-
ates allogeneic host-versus-graft response and delays skin graft rejection 
through activation of cannabinoid receptor 1 and induction of myeloid- 
derived suppressor cells. J Leukoc Biol (2015) 98:435–47. doi:10.1189/
jlb.3A0115-030RR 
63. Lee W-S, Erdelyi K, Matyas C, Mukhopadhyay P, Varga ZV, Liaudet L, 
et  al. Cannabidiol limits Tcell-mediated chronic autoimmune myocarditis: 
implications to autoimmune disorders and organ transplantation. Mol 
Med (2016). doi:10.2119/molmed.2016.00007 
64. Pandey R, Hegde VL, Nagarkatti M, Nagarkatti PS. Targeting cannabi-
noid receptors as a novel approach in the treatment of graft-versus-host 
disease: evidence from an experimental murine model. J Pharmacol Exp Ther 
(2011) 338:819–28. doi:10.1124/jpet.111.182717 
65. Yeshurun M, Shpilberg O, Herscovici C, Shargian L, Dreyer J, Peck A, 
et  al. Cannabidiol for the prevention of graft-versus-host-disease after 
allogeneic hematopoietic cell transplantation: results of a phase II study. 
Biol Blood Marrow Transplant (2015) 21:1770–5. doi:10.1016/j.bbmt.2015. 
05.018 
66. Pradhan V, Borse V, Ghosh K. PTPN22 gene polymorphisms in autoim-
mune diseases with special reference to systemic lupus erythematosus 
disease susceptibility. J Postgrad Med (2010) 56:239–42. doi:10.4103/0022- 
3859.68651 
67. Sipe JC, Arbour N, Gerber A, Beutler E. Reduced endocannabinoid 
immune modulation by a common cannabinoid 2 (CB2) receptor gene 
poly morphism: possible risk for autoimmune disorders. J Leukoc Biol (2005) 
78:231–8. doi:10.1189/jlb.0205111 
68. Mahmoud Gouda H, Mohamed Kamel NR. Cannabinoid CB2 receptor 
gene (CNR2) polymorphism is associated with chronic childhood immune 
thrombocytopenia in Egypt. Blood Coagul Fibrinolysis (2013) 24:247–51. 
doi:10.1097/MBC.0b013e32835aba1d 
69. Rossi F, Bellini G, Tolone C, Luongo L, Mancusi S, Papparella A, et  al.  
The cannabinoid receptor type 2 Q63R variant increases the risk of celiac 
disease: implication for a novel molecular biomarker and future therapeutic 
intervention. Pharmacol Res (2012) 66:88–94. doi:10.1016/j.phrs.2012. 
03.011 
70. Coppola N, Zampino R, Bellini G, Stanzione M, Capoluongo N, 
Marrone A, et  al. CB2-63 polymorphism and immune-mediated diseases 
associated with HCV chronic infection. Dig Liver Dis (2016) 48:1364–9. 
doi:10.1016/j.dld.2016.07.005 
71. Coppola N, Zampino R, Bellini G, Macera M, Marrone A, Pisaturo M, 
et al. Association between a polymorphism in cannabinoid receptor 2 and 
severe necroinflammation in patients with chronic hepatitis C. Clin Gas-
troenterol Hepatol (2014) 12:334–40. doi:10.1016/j.cgh.2013.05.008 
72. Gui H, Tong Q, Qu W, Mao C-M, Dai S-M. The endocannabinoid system 
and its therapeutic implications in rheumatoid arthritis. Int Immunophar-
macol (2015) 26:86–91. doi:10.1016/j.intimp.2015.03.006 
73. Fitzcharles M-A, McDougall J, Ste-Marie PA, Padjen I. Clinical implications 
for cannabinoid use in the rheumatic diseases: potential for help or harm? 
Arthritis Rheum (2012) 64:2417–25. doi:10.1002/art.34522 
74. Sido JM, Nagarkatti PS, Nagarkatti M. Role of endocannabinoid activa tion 
of peripheral CB1 receptors in the regulation of autoimmune disease. Int 
Rev Immunol (2015) 34:403–14. doi:10.3109/08830185.2014.921165 
75. Katchan V, David P, Shoenfeld Y. Cannabinoids and autoimmune diseases: 
a systematic review. Autoimmun Rev (2016) 15:513–28. doi:10.1016/j.autrev. 
2016.02.008 
76. Li X, Kaminski NE, Fischer LJ. Examination of the immunosuppres sive 
effect of delta9-tetrahydrocannabinol in streptozotocin-induced auto-
immune diabetes. Int Immunopharmacol (2001) 1:699–712. doi:10.1016/
S1567-5769(01)00003-0 
77. Marquéz L, Suárez J, Iglesias M, Bermudez-Silva FJ, Rodríguez de Fonseca F, 
Andreu M. Ulcerative colitis induces changes on the expression of the 
endocannabinoid system in the human colonic tissue. PLoS One (2009) 
4:e6893. doi:10.1371/journal.pone.0006893 
78. Naftali T, Mechulam R, Lev LB, Konikoff FM. Cannabis for inflammatory 
bowel disease. Dig Dis (2014) 32:468–74. doi:10.1159/000358155 
79. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the 
gas trointestinal tract: a regulatory system in states of inflammation. Br J Phar-
macol (2008) 153:263–70. doi:10.1038/sj.bjp.0707486 
80. Katz D, Katz I, Porat-Katz BS, Shoenfeld Y. Medical Cannabis: another 
piece in the mosaic of autoimmunity? Clin Pharmacol Ther (2017) 101:230–8. 
doi:10.1002/cpt.568 
81. Lehmann C, Fisher NB, Tugwell B, Szczesniak A, Kelly M, Zhou J. 
Experimental cannabidiol treatment reduces early pancreatic inflammation 
in type 1 diabetes. Clin Hemorheol Microcirc (2016) 64:655–62. doi:10.3233/
CH-168021 
82. Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R, Fezza F, et  al. The 
endocannabinoid system is dysregulated in multiple sclerosis and in 
exper imental autoimmune encephalomyelitis. Brain (2007) 130:2543–53. 
doi:10.1093/brain/awm160 
83. Sexton M, Cudaback E, Abdullah RA, Finnell J, Mischley LK, Rozga M, 
et  al. Cannabis use by individuals with multiple sclerosis: effects on 
specific immune parameters. Inflammopharmacology (2014) 22:295–303. 
doi:10.1007/s10787-014-0214-z 
84. Fitzpatrick J-MK, Downer EJ. Toll-like receptor signalling as a cannabi-
noid target in multiple sclerosis. Neuropharmacology (2016) 113:618–26. 
doi:10.1016/j.neuropharm.2016.04.009 
85. Haugh O, Penman J, Irving AJ, Campbell VA. The emerging role of the 
cannabinoid receptor family in peripheral and neuro-immune interactions. 
Curr Drug Targets (2016) 17:1834–40. doi:10.2174/1389450117666160112
113703 
86. Molina-Holgado F, Molina-Holgado E, Guaza C. The endogenous can-
nabinoid anandamide potentiates interleukin-6 production by astrocytes 
infected with Theiler’s murine encephalomyelitis virus by a receptor- 
mediated pathway. FEBS Lett (1998) 433:139–42. doi:10.1016/S0014-5793 
(98)00851-5 
87. Ribeiro R, Yu F, Wen J, Vana A, Zhang Y. Therapeutic potential of a novel 
cannabinoid agent CB52 in the mouse model of experimental autoim-
mune encephalomyelitis. Neuroscience (2013) 254:427–42. doi:10.1016/j.
neuroscience.2013.09.005 
88. Lourbopoulos A, Grigoriadis N, Lagoudaki R, Touloumi O, Polyzoidou E, 
Mavromatis I, et  al. Administration of 2-arachidonoylglycerol ame-
liorates both acute and chronic experimental autoimmune encepha-
lomyelitis. Brain Res (2011) 1390:126–41. doi:10.1016/j.brainres.2011. 
03.020 
89. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. Modulation of 
the cannabinoid CB2 receptor in microglial cells in response to inflamma-
tory stimuli. J Neurochem (2005) 95:437–45. doi:10.1111/j.1471-4159.2005. 
03380.x 
90. Lou Z-Y, Chen C, He Q, Zhao C-B, Xiao B-G. Targeting CB(2) receptor 
as a neuroinflammatory modulator in experimental autoimmune enceph-
alomyelitis. Mol Immunol (2011) 49:453–61. doi:10.1016/j.molimm.2011. 
09.016 
91. Kong W, Li H, Tuma RF, Ganea D. Selective CB2 receptor activation ame-
liorates EAE by reducing Th17 differentiation and immune cell accumu-
lation in the CNS. Cell Immunol (2014) 287:1–17. doi:10.1016/j.cellimm. 
2013.11.002 
92. Shi Y, Duan Y-H, Ji Y-Y, Wang Z-L, Wu Y-R, Gunosewoyo H, et  al. 
Amidoalkylindoles as potent and selective cannabinoid type 2 receptor 
agonists with in vivo efficacy in a mouse model of multiple sclerosis. J Med 
Chem (2017) 60:7067–83. doi:10.1021/acs.jmedchem.7b00724 
93. Annunziata P, Cioni C, Mugnaini C, Corelli F. Potent immunomodula-
tory activity of a highly selective cannabinoid CB2 agonist on immune cells 
from healthy subjects and patients with multiple sclerosis. J Neuroimmunol 
(2017) 303:66–74. doi:10.1016/j.jneuroim.2016.12.009 
94. Morales P, Gómez-Cañas M, Navarro G, Hurst DP, Carrillo-Salinas FJ, 
Lagartera L, et  al. Chromenopyrazole, a versatile cannabinoid scaffold 
with in  vivo activity in a model of multiple sclerosis. J Med Chem (2016) 
59:6753–71. doi:10.1021/acs.jmedchem.6b00397 
12
Oláh et al. Immunological Roles of Cannabinoid Signaling
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1487
95. Malfitano AM, Laezza C, Pisanti S, Manera C, Bifulco M. Immuno-
modulatory properties of a quinolin-2-(1H)-on-3-carboxamide derivative: 
relevance in multiple sclerosis. Recent Pat CNS Drug Discov (2016) 10:113–21. 
doi:10.2174/1574889810666160421121726 
96. Correa F, Hernangómez M, Mestre L, Loría F, Spagnolo A, Docagne F, 
et  al. Anandamide enhances IL-10 production in activated microglia by 
targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB. Glia  
(2010) 58:135–47. doi:10.1002/glia.20907 
97. Correa F, Hernangómez-Herrero M, Mestre L, Loría F, Docagne F, 
Guaza C. The endocannabinoid anandamide downregulates IL-23 and IL-12 
subunits in a viral model of multiple sclerosis: evidence for a cross-talk 
between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain Behav 
Immun (2011) 25:736–49. doi:10.1016/j.bbi.2011.01.020 
98. Correa F, Docagne F, Mestre L, Loría F, Hernangómez M, Borrell J, 
et  al. Cannabinoid system and neuroinflammation: implications for mul-
tiple sclerosis. Neuroimmunomodulation (2007) 14:182–7. doi:10.1159/ 
000110644 
99. Ramirez SH, Haskó J, Skuba A, Fan S, Dykstra H, McCormick R, 
et al. Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial 
cell interactions and blood-brain barrier dysfunction under inflammatory 
conditions. J Neurosci (2012) 32:4004–16. doi:10.1523/JNEUROSCI.4628- 
11.2012 
100. Mecha M, Carrillo-Salinas FJ, Feliú A, Mestre L, Guaza C. Microglia 
activation states and cannabinoid system: therapeutic implications. Phar-
macol Ther (2016) 166:40–55. doi:10.1016/j.pharmthera.2016.06.011 
101. Carrillo-Salinas FJ, Navarrete C, Mecha M, Feliú A, Collado JA, Cantarero I, 
et al. A cannabigerol derivative suppresses immune responses and protects 
mice from experimental autoimmune encephalomyelitis. PLoS One (2014) 
9:e94733. doi:10.1371/journal.pone.0094733 
102. Alberti TB, Barbosa WLR, Vieira JLF, Raposo NRB, Dutra RC. (-)-β- 
caryophyllene, a CB2 receptor-selective phytocannabinoid, suppresses motor 
paralysis and neuroinflammation in a murine model of multiple sclerosis. 
Int J Mol Sci (2017) 18. doi:10.3390/ijms18040691 
103. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 
(2006) 147(Suppl 1):S163–71. doi:10.1038/sj.bjp.0706406 
104. Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, et al. 
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis 
spasticity. J Neurol Neurosurg Psychiatry (2016) 87:944–51. doi:10.1136/
jnnp-2015-312591 
105. Lanza G, Ferri R, Bella R, Ferini-Strambi L. The impact of drugs for multiple 
sclerosis on sleep. Mult Scler (2017) 23:5–13. doi:10.1177/1352458516664034 
106. Marinelli L, Mori L, Canneva S, Colombano F, Currà A, Fattapposta F, et al.  
The effect of cannabinoids on the stretch reflex in multiple sclerosis 
spasticity. Int Clin Psychopharmacol (2016) 31:232–9. doi:10.1097/YIC. 
0000000000000126 
107. van Amerongen G, Kanhai K, Baakman AC, Heuberger J, Klaassen E, 
Beumer TL, et al. Effects on spasticity and neuropathic pain of an oral for-
mulation of Δ9-tetrahydrocannabinol in patients with progressive multiple 
sclerosis. Clin Ther (2017). doi:10.1016/j.clinthera.2017.01.016 
108. Abo Youssef N, Schneider MP, Mordasini L, Ineichen BV, Bachmann LM, 
Chartier-Kastler E, et  al. Cannabinoids for treating neurogenic lower 
urinary tract dysfunction in patients with multiple sclerosis: a systematic 
review and meta-analysis. BJU Int (2017) 119:515–21. doi:10.1111/bju. 
13759 
109. Maccarrone M, Maldonado R, Casas M, Henze T, Centonze D. 
Cannabinoids therapeutic use: what is our current understanding follow-
ing the introduction of THC, THC:CBD oromucosal spray and others? 
Expert Rev Clin Pharmacol (2017) 10:443–55. doi:10.1080/17512433.2017. 
1292849 
110. Behm K, Morgan P. The effect of symptom-controlling medication on gait 
outcomes in people with multiple sclerosis: a systematic review. Disabil 
Rehabil (2017) 4:1–12. doi:10.1080/09638288.2017.1309581 
111. Squintani G, Donato F, Turri M, Deotto L, Teatini F, Moretto G, et  al.  
Cortical and spinal excitability in patients with multiple sclerosis and spas-
ticity after oromucosal cannabinoid spray. J Neurol Sci (2016) 370:263–8. 
doi:10.1016/j.jns.2016.09.054 
112. Meza R, Peña J, García K, Corsi O, Rada G. Are cannabinoids effective 
in multiple sclerosis? Medwave (2017) 17:e6865. doi:10.5867/medwave. 
2017.6865 
113. Katona S, Kaminski E, Sanders H, Zajicek J. Cannabinoid influence on 
cytokine profile in multiple sclerosis. Clin Exp Immunol (2005) 140:580–5. 
doi:10.1111/j.1365-2249.2005.02803.x 
114. Cannabinoid Buccal Spray for Chronic Non-Cancer or Neuropathic Pain: 
A Review of Clinical Effectiveness, Safety, and Guidelines. Ottawa, ON: 
Canadian Agency for Drugs and Technologies in Health (2016). Available 
from: http://www.ncbi.nlm.nih.gov/books/NBK395789/
115. Saccà F, Pane C, Carotenuto A, Massarelli M, Lanzillo R, Florio EB, et  al.  
The use of medical-grade Cannabis in patients non-responders to nabiximols. 
J Neurol Sci (2016) 368:349–51. doi:10.1016/j.jns.2016.07.059 
116. Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB. Delta 9- 
tetrahydrocannabinol: a novel treatment for experimental autoimmune 
encephalomyelitis. J Neuroimmunol (1989) 23:73–81. doi:10.1016/0165- 
5728(89)90075-1 
117. Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D. Neuroprotec-
tion in experimental autoimmune encephalomyelitis and progressive mul-
tiple sclerosis by Cannabis-based cannabinoids. J Neuroimmune Pharmacol 
(2015) 10:281–92. doi:10.1007/s11481-014-9575-8 
118. Giacoppo S, Pollastro F, Grassi G, Bramanti P, Mazzon E. Target regulation 
of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental 
multiple sclerosis. Fitoterapia (2017) 116:77–84. doi:10.1016/j.fitote.2016. 
11.010 
119. Kozela E, Juknat A, Gao F, Kaushansky N, Coppola G, Vogel Z. 
Pathways and gene networks mediating the regulatory effects of canna-
bidiol, a nonpsychoactive cannabinoid, in autoimmune T  cells. J Neuro-
inflammation (2016) 13:136. doi:10.1186/s12974-016-0603-x 
120. Mecha M, Feliú A, Iñigo PM, Mestre L, Carrillo-Salinas FJ, Guaza C. 
Cannabidiol provides long-lasting protection against the deleterious 
effects of inflammation in a viral model of multiple sclerosis: a role for 
A2A receptors. Neurobiol Dis (2013) 59:141–50. doi:10.1016/j.nbd.2013. 
06.016 
121. Ribeiro A, Ferraz-de-Paula V, Pinheiro ML, Vitoretti LB, Mariano-Souza DP, 
Quinteiro-Filho WM, et al. Cannabidiol, a non-psychotropic plant-derived 
cannabinoid, decreases inflammation in a murine model of acute lung injury: 
role for the adenosine A(2A) receptor. Eur J Pharmacol (2012) 678:78–85. 
doi:10.1016/j.ejphar.2011.12.043 
122. Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllõsi AG, Czifra G, et  al. 
Cannabidiol exerts sebostatic and antiinflammatory effects on human 
sebocytes. J Clin Invest (2014) 124:3713–24. doi:10.1172/JCI64628 
123. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucle-
oside transporter by cannabidiol: a mechanism of cannabinoid immunosup-
pression. Proc Natl Acad Sci U S A (2006) 103:7895–900. doi:10.1073/pnas. 
0511232103 
124. Birdsall SM, Birdsall TC, Tims LA. The use of medical marijuana in cancer. 
Curr Oncol Rep (2016) 18:40. doi:10.1007/s11912-016-0530-0 
125. Velasco G, Sánchez C, Guzmán M. Anticancer mechanisms of cannabinoids. 
Curr Oncol (2016) 23:S23–32. doi:10.3747/co.23.3080 
126. Nikan M, Nabavi SM, Manayi A. Ligands for cannabinoid receptors, 
promising anticancer agents. Life Sci (2016) 146:124–30. doi:10.1016/j.lfs. 
2015.12.053 
127. Velasco G, Sánchez C, Guzmán M. Endocannabinoids and cancer. Handb 
Exp Pharmacol (2015) 231:449–72. doi:10.1007/978-3-319-20825-1_16 
128. Velasco G, Hernández-Tiedra S, Dávila D, Lorente M. The use of canna-
binoids as anticancer agents. Prog Neuropsychopharmacol Biol Psychiatry 
(2016) 64:259–66. doi:10.1016/j.pnpbp.2015.05.010 
129. McAllister SD, Soroceanu L, Desprez P-Y. The antitumor activity of plant- 
derived non-psychoactive cannabinoids. J Neuroimmune Pharmacol (2015) 
10:255–67. doi:10.1007/s11481-015-9608-y 
130. Pyszniak M, Tabarkiewicz J, Łuszczki JJ. Endocannabinoid system as a 
regulator of tumor cell malignancy – biological pathways and clinical sig-
nificance. Onco Targets Ther (2016) 9:4323–36. doi:10.2147/OTT.S106944 
131. Ramer R, Hinz B. Antitumorigenic targets of cannabinoids – current status 
and implications. Expert Opin Ther Targets (2016) 20:1219–35. doi:10.1080/
14728222.2016.1177512 
132. Javid FA, Phillips RM, Afshinjavid S, Verde R, Ligresti A. Cannabinoid 
pharmacology in cancer research: a new hope for cancer patients? Eur 
J Pharmacol (2016) 775:1–14. doi:10.1016/j.ejphar.2016.02.010 
133. Tegeder I. Endocannabinoids as guardians of metastasis. Int J Mol Sci (2016) 
17:230. doi:10.3390/ijms17020230 
13
Oláh et al. Immunological Roles of Cannabinoid Signaling
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1487
134. Fraguas-Sánchez AI, Fernández-Carballido A, Torres-Suárez AI. Phyto-, 
endo- and synthetic cannabinoids: promising chemotherapeutic agents in 
the treatment of breast and prostate carcinomas. Expert Opin Investig Drugs 
(2016) 25:1311–23. doi:10.1080/13543784.2016.1236913 
135. Carpi S, Fogli S, Polini B, Montagnani V, Podestà A, Breschi MC, et  al.  
Tumor-promoting effects of cannabinoid receptor type 1 in human mela-
noma cells. Toxicol In Vitro (2017) 40:272–9. doi:10.1016/j.tiv.2017.01.018 
136. Wang J, Xu Y, Zou Y, Zhu L, Dong B, Huang J, et  al. Overexpression of 
cannabinoid receptor 1 promotes renal cell carcinoma progression. Tumour 
Biol (2016) 37(12):16237–47. doi:10.1007/s13277-016-5447-6 
137. Martínez-Martínez E, Martín-Ruiz A, Martín P, Calvo V, Provencio M, 
García JM. CB2 cannabinoid receptor activation promotes colon cancer pro-
gression via AKT/GSK3β signaling pathway. Oncotarget (2016) 7:68781–91. 
doi:10.18632/oncotarget.11968 
138. Pokrywka M, Góralska J, Solnica B. Cannabinoids – a new weapon against 
cancer? Postepy Hig Med Dosw (Online) (2016) 70:1309–20. doi:10.5604/ 
17322693.1227443 
139. Ladin DA, Soliman E, Griffin L, Van Dross R. Preclinical and clinical assess-
ment of cannabinoids as anti-cancer agents. Front Pharmacol (2016) 7:361. 
doi:10.3389/fphar.2016.00361 
140. McKallip RJ, Nagarkatti M, Nagarkatti PS. Delta-9-tetrahydrocannabinol 
enhances breast cancer growth and metastasis by suppression of the 
antitumor immune response. J Immunol (2005) 174:3281–9. doi:10.4049/
jimmunol.174.6.3281 
141. Gao W, Xiong Y, Li Q, Yang H. Inhibition of toll-like receptor signaling as 
a promising therapy for inflammatory diseases: a journey from molecular 
to nano therapeutics. Front Physiol (2017) 8:508. doi:10.3389/fphys.2017. 
00508 
142. Fang H, Jiang W, Cheng J, Lu Y, Liu A, Kan L, et al. Balancing innate immu-
nity and inflammatory state via modulation of neutrophil function: a novel 
strategy to fight sepsis. J Immunol Res (2015) 2015:187048. doi:10.1155/2015/ 
187048 
143. Sivak KV, Vasin AV, Egorov VV, Tsevtkov VB, Kuzmich NN, Savina VA, 
et  al. [Adenosine A2A receptor as a drug target for treatment of sepsis]. 
Mol Biol (Mosk) (2016) 50:231–45. doi:10.7868/S0026898416020233 
144. Sardinha J, Kelly MEM, Zhou J, Lehmann C. Experimental cannabinoid 2 
receptor-mediated immune modulation in sepsis. Mediators Inflamm (2014) 
2014:978678. doi:10.1155/2014/978678 
145. Tschöp J, Kasten KR, Nogueiras R, Goetzman HS, Cave CM, England LG, 
et al. The cannabinoid receptor 2 is critical for the host response to sepsis. 
J Immunol (2009) 183:499–505. doi:10.4049/jimmunol.0900203 
146. Croxford JL, Wang K, Miller SD, Engman DM, Tyler KM. Effects of 
cannabinoid treatment on Chagas disease pathogenesis: balancing inhi-
bition of parasite invasion and immunosuppression. Cell Microbiol (2005) 
7:1592–602. doi:10.1111/j.1462-5822.2005.00577.x 
147. Alferink J, Specht S, Arends H, Schumak B, Schmidt K, Ruland C, et  al. 
Cannabinoid receptor 2 modulates susceptibility to experimental cerebral 
malaria through a CCL17-dependent mechanism. J Biol Chem (2016) 
291:19517–31. doi:10.1074/jbc.M116.746594 
148. Sun X, Cappelletti M, Li Y, Karp CL, Divanovic S, Dey SK. Cnr2 defi-
ciency confers resistance to inflammation-induced preterm birth in mice. 
Endocrinology (2014) 155:4006–14. doi:10.1210/en.2014-1387 
149. Dotsey E, Ushach I, Pone E, Nakajima R, Jasinskas A, Argueta DA, et  al. 
Transient cannabinoid receptor 2 blockade during immunization heightens 
intensity and breadth of antigen-specific antibody responses in young and 
aged mice. Sci Rep (2017) 7:42584. doi:10.1038/srep42584 
150. Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Stavri M, 
et al. Antibacterial cannabinoids from Cannabis sativa: a structure-activity 
study. J Nat Prod (2008) 71:1427–30. doi:10.1021/np8002673 
151. Tahamtan A, Tavakoli-Yaraki M, Rygiel TP, Mokhtari-Azad T, Salimi V. 
Effects of cannabinoids and their receptors on viral infections. J Med Virol 
(2016) 88:1–12. doi:10.1002/jmv.24292 
152. Barichello T, Ceretta RA, Generoso JS, Moreira AP, Simões LR, Comim CM, 
et  al. Cannabidiol reduces host immune response and prevents cognitive 
impairments in Wistar rats submitted to pneumococcal meningitis. Eur 
J Pharmacol (2012) 697:158–64. doi:10.1016/j.ejphar.2012.09.053 
153. Chandra LC, Kumar V, Torben W, Vande Stouwe C, Winsauer P, Amedee A, 
et al. Chronic administration of Δ9-tetrahydrocannabinol induces intestinal 
anti-inflammatory microRNA expression during acute simian immuno-
deficiency virus infection of rhesus macaques. J Virol (2015) 89:1168–81. 
doi:10.1128/JVI.01754-14 
154. Simon L, Song K, Vande Stouwe C, Hollenbach A, Amedee A, Mohan M, 
et  al. Δ9-Tetrahydrocannabinol (Δ9-THC) promotes neuroimmune- 
modulatory microRNA profile in striatum of simian immunodeficiency 
virus (SIV)-infected macaques. J Neuroimmune Pharmacol (2016) 11: 
192–213. doi:10.1007/s11481-015-9645-6 
155. Molina PE, Winsauer P, Zhang P, Walker E, Birke L, Amedee A, 
et  al. Cannabinoid administration attenuates the progression of simian 
immunodeficiency virus. AIDS Res Hum Retroviruses (2011) 27:585–92. 
doi:10.1089/aid.2010.0218 
156. Chen W, Crawford RB, Kaplan BLF, Kaminski NE. Modulation of HIVGP120 
antigen-specific immune responses in  vivo by Δ9-tetrahydrocannabinol. 
J Neuroimmune Pharmacol (2015) 10:344–55. doi:10.1007/s11481-015-9597-x 
157. Marcellin F, Lions C, Rosenthal E, Roux P, Sogni P, Wittkop L, 
et al. No significant effect of Cannabis use on the count and percentage of 
circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-
HEPAVIH French cohort). Drug Alcohol Rev (2017) 36:227–38. doi:10.1111/
dar.12398 
158. Molina PE, Amedee A, LeCapitaine NJ, Zabaleta J, Mohan M, Winsauer P, 
et al. Cannabinoid neuroimmune modulation of SIV disease. J Neuroimmune 
Pharmacol (2011) 6:516–27. doi:10.1007/s11481-011-9301-8 
159. Reznik SE, Gardner EL, Ashby CR. Cannabidiol: a potential treatment 
for post Ebola syndrome? Int J Infect Dis (2016) 52:74–6. doi:10.1016/j.
ijid.2016.09.020 
160. Lowe HIC, Toyang NJ, McLaughlin W. Potential of cannabidiol for the 
treatment of viral hepatitis. Pharmacognosy Res (2017) 9:116–8. doi:10.4103/ 
0974-8490.199780 
161. Campos AC, Brant F, Miranda AS, Machado FS, Teixeira AL. 
Cannabidiol increases survival and promotes rescue of cognitive function 
in a murine model of cerebral malaria. Neuroscience (2015) 289:166–80. 
doi:10.1016/j.neuroscience.2014.12.051 
162. Blumstein GW, Parsa A, Park AK, McDowell BLP, Arroyo-Mendoza M, 
Girguis M, et  al. Effect of delta-9-tetrahydrocannabinol on mouse resis-
tance to systemic Candida albicans infection. PLoS One (2014) 9:e103288. 
doi:10.1371/journal.pone.0103288 
163. Newton CA, Chou P-J, Perkins I, Klein TW. CB(1) and CB(2) cannabinoid 
receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-
induced T helper cell shift following immune activation by Legionella pneu-
mophila infection. J Neuroimmune Pharmacol (2009) 4:92–102. doi:10.1007/
s11481-008-9126-2 
164. Karmaus PWF, Chen W, Crawford R, Kaplan BLF, Kaminski NE. Δ9-
tetrahydrocannabinol impairs the inflammatory response to influenza 
infection: role of antigen-presenting cells and the cannabinoid receptors 1 
and 2. Toxicol Sci (2013) 131:419–33. doi:10.1093/toxsci/kfs315 
165. Roth MD, Tashkin DP, Whittaker KM, Choi R, Baldwin GC. Tetra-
hydrocannabinol suppresses immune function and enhances HIV replica-
tion in the huPBL-SCID mouse. Life Sci (2005) 77:1711–22. doi:10.1016/j.
lfs.2005.05.014 
166. Henriquez JE, Rizzo MD, Schulz MA, Crawford RB, Gulick P, Kaminski NE. 
Δ9-tetrahydrocannabinol suppresses secretion of IFNα by plasmacytoid 
dendritic cells from healthy and HIV-infected individuals. J Acquir Immune 
Defic Syndr (2017) 75:588–96. doi:10.1097/QAI.0000000000001449 
167. Roth MD, Baldwin GC, Tashkin DP. Effects of delta-9-tetrahydrocan-
nabinol on human immune function and host defense. Chem Phys Lipids  
(2002) 121:229–39. doi:10.1016/S0009-3084(02)00159-7 
168. Zumbrun EE, Sido JM, Nagarkatti PS, Nagarkatti M. Epigenetic regulation 
of immunological alterations following prenatal exposure to marijuana 
cannabinoids and its long term consequences in offspring. J Neuroimmune 
Pharmacol (2015) 10:245–54. doi:10.1007/s11481-015-9586-0 
169. Lombard C, Hegde VL, Nagarkatti M, Nagarkatti PS. Perinatal exposure 
to Δ9-tetrahydrocannabinol triggers profound defects in T  cell differenti-
ation and function in fetal and postnatal stages of life, including decreased 
responsiveness to HIV antigens. J Pharmacol Exp Ther (2011) 339:607–17. 
doi:10.1124/jpet.111.181206 
170. Moretti S, Franchi S, Castelli M, Amodeo G, Somaini L, Panerai A, et  al. 
Exposure of adolescent mice to delta-9-tetrahydrocannabinol induces 
14
Oláh et al. Immunological Roles of Cannabinoid Signaling
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1487
long-lasting modulation of pro- and anti-inflammatory cytokines in 
hypothalamus and hippocampus similar to that observed for peripheral 
macrophages. J Neuroimmune Pharmacol (2015) 10:371–9. doi:10.1007/
s11481-015-9592-2 
171. Moretti S, Castelli M, Franchi S, Raggi MA, Mercolini L, Protti M, et  al. 
Δ9-Tetrahydrocannabinol-induced anti-inflammatory responses in ado-
lescent mice switch to proinflammatory in adulthood. J Leukoc Biol (2014) 
96:523–34. doi:10.1189/jlb.3HI0713-406RR 
172. Dax EM, Pilotte NS, Adler WH, Nagel JE, Lange WR. The effects of 9-ene- 
tetrahydrocannabinol on hormone release and immune function. J Steroid 
Biochem (1989) 34:263–70. doi:10.1016/0022-4731(89)90090-3 
173. Utomo WK, de Vries M, Braat H, Bruno MJ, Parikh K, Comalada M, 
et  al. Modulation of human peripheral blood mononuclear cell signaling 
by medicinal cannabinoids. Front Mol Neurosci (2017) 10:14. doi:10.3389/
fnmol.2017.00014 
174. El-Gohary M, Eid MA. Effect of cannabinoid ingestion (in the form of 
bhang) on the immune system of high school and university students. Hum 
Exp Toxicol (2004) 23:149–56. doi:10.1191/0960327104ht426oa 
175. Bénard G, Massa F, Puente N, Lourenço J, Bellocchio L, Soria-Gómez E, 
et  al. Mitochondrial CB1 receptors regulate neuronal energy metabolism. 
Nat Neurosci (2012) 15:558–64. doi:10.1038/nn.3053 
176. Hebert-Chatelain E, Desprez T, Serrat R, Bellocchio L, Soria-Gomez E, 
Busquets-Garcia A, et  al. A cannabinoid link between mitochondria and 
memory. Nature (2016) 539:555–9. doi:10.1038/nature20127 
177. Bilkei-Gorzo A, Albayram O, Draffehn A, Michel K, Piyanova A, 
Oppenheimer H, et  al. A chronic low dose of Δ(9)-tetrahydrocannabinol 
(THC) restores cognitive function in old mice. Nat Med (2017) 23:782–7. 
doi:10.1038/nm.4311 
178. Bilkei-Gorzo A, Drews E, Albayram Ö, Piyanova A, Gaffal E, Tueting T, 
et  al. Early onset of aging-like changes is restricted to cognitive abilities 
and skin structure in Cnr1−/− mice. Neurobiol Aging (2012) 33:200.e11–22. 
doi:10.1016/j.neurobiolaging.2010.07.009 
179. Dudok B, Barna L, Ledri M, Szabó SI, Szabadits E, Pintér B, et  al.  
Cell-specific STORM super-resolution imaging reveals nanoscale organiza-
tion of cannabinoid signaling. Nat Neurosci (2015) 18:75–86. doi:10.1038/ 
nn.3892 
180. Topol EJ, Bousser M-G, Fox KAA, Creager MA, Despres J-P, Easton JD, 
et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): 
a randomised, multicentre, placebo-controlled trial. Lancet (2010) 376: 
517–23. doi:10.1016/S0140-6736(10)60935-X 
181. von Schaper E. Bial incident raises FAAH suspicions. Nat Biotechnol (2016) 
34:223. doi:10.1038/nbt0316-223a 
182. van Esbroeck ACM, Janssen APA, Cognetta AB, Ogasawara D, Shpak G, 
van der Kroeg M, et  al. Activity-based protein profiling reveals off-target 
proteins of the FAAH inhibitor BIA 10-2474. Science (2017) 356:1084–7. 
doi:10.1126/science.aaf7497 
183. Scott KA, Dalgleish AG, Liu WM. Anticancer effects of phytocannabinoids 
used with chemotherapy in leukaemia cells can be improved by altering 
the sequence of their administration. Int J Oncol (2017) 51:369–77. 
doi:10.3892/ijo.2017.4022 
184. Agudelo M, Figueroa G, Yndart A, Casteleiro G, Muñoz K, Samikkannu T, 
et  al. Alcohol and cannabinoids differentially affect HIV infection and 
function of human monocyte-derived dendritic cells (MDDC). Front 
Microbiol (2015) 6:1452. doi:10.3389/fmicb.2015.01452 
185. Patterson Z, Young M, Vaccarino F. Novel psychoactive substances: what 
educators need to know. Clin Pharmacol Ther (2017) 101:173–5. doi:10.1002/
cpt.538 
186. Sexton M, Silvestroni A, Möller T, Stella N. Differential migratory prop-
erties of monocytes isolated from human subjects naïve and non-naïve to 
Cannabis. Inflammopharmacology (2013) 21:253–9. doi:10.1007/s10787-012- 
0133-9 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Oláh, Szekanecz and Bíró. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) or licensor are credited and that the original publication in this journal 
is cited, in accordance with accepted academic practice. No use, distribution or 
reproduction is permitted which does not comply with these terms.
